Personalized Medicine News and Research

RSS

Interferon beta not associated with less progression of disability in patients with RRMS

Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Viewpoints: Calif. could take a lesson from Wis. reforms; Republican advocates a 'Nixon to China' embrace of Medicare for all

The state's teachers union, Wisconsinites learned, had used its power to collectively bargain for healthcare benefits to demand that local school districts provide coverage through a nonprofit insurer affiliated with the union. Once the state ended bargaining on healthcare, school boards began competitively bidding out their health insurance. By the opening of the new school year in September, just two months after the budget bill went into effect, 23 districts had rebid their contracts, saving $16 million, or an average of $211 per student.

17 Jul 2012

Life Technologies acquires Navigenics

Life Technologies Corporation today announced the acquisition of Navigenics, Inc. This acquisition represents Life Technologies' first step in executing against a strategy to build out its molecular diagnostics business through internal development, partnerships and select acquisitions.

17 Jul 2012

Book explains complex world of personalized medicine

Personalized medicine has promised to radically change the way we look at health and disease. Talk of tailored drug therapies and early detection of cancer has captured the attention of scientists and lay people alike. So when will patients start to reap the benefits of this medical revolution?

11 Jul 2012

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

New research from University of the Sciences' Mayes College of Healthcare Business and Policy suggests that MammaPrint - a gene expression profiling (GEP) test used to identify whether women with early-stage breast cancer would benefit from chemotherapy - is the more cost-effective and clinically-useful test than the most frequently used GEP in practice in the United States today.

10 Jul 2012

BioView, ScreenCell enter collaboration agreement for imaging of CTC

BioView Ltd. and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit.

9 Jul 2012

Study shows cells from different Parkinson’s patients have unique drug responses

Researchers have taken a step toward personalized medicine for Parkinson's disease, by investigating signs of the disease in patient-derived cells and testing how the cells respond to drug treatments.

5 Jul 2012

Researchers discover new gene mutations associated with megalencephaly

A research team led by Seattle Children's Research Institute has discovered new gene mutations associated with markedly enlarged brain size, or megalencephaly.

30 Jun 2012

Millennium introduces novel pharmacogenetic testing

Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing.

29 Jun 2012

New paper discusses potential of tumor-derived microvesicles

A new paper by Crislyn D'Souza-Schorey, professor of biological sciences at the University of Notre Dame, discusses the biology of tumor-derived microvesicles and their clinical application as circulating biomarkers. Microvesicles are membrane-bound sacs released by tumor cells and can be detected in the body fluids of cancer patients.

23 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine

Gentris Corporation, a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine.

22 Jun 2012

Variations in microRNA expression within breast tumors can lead to sampling bias

Certain short strands of RNA, known as microRNAs (miRNAs), have been linked to the progression and metastasis of breast cancer and may provide information about prognosis. However, studies of miRNA expression profiles often report conflicting findings. While the potential for using miRNAs in breast cancer diagnosis is promising, scientists report in a new study published online today in The Journal of Molecular Diagnostics that differences in the amount and types of miRNA within breast tumors can be misleading.

15 Jun 2012

Enzo Biochem third quarter total revenue increases 4% to $26 million

Enzo Biochem, Inc. today reported results for the fiscal third quarter ended April 30, 2012.

12 Jun 2012

Sapio announces availability of Exemplar Biomarker Discovery LIMS

Sapio Sciences is pleased to announce the immediate availability of Exemplar Biomarker Discovery LIMS.

5 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

Personalized Medicine News and Research

Interferon beta not associated with less progression of disability in patients with RRMS

Viewpoints: Calif. could take a lesson from Wis. reforms; Republican advocates a 'Nixon to China' embrace of Medicare for all

Life Technologies acquires Navigenics

Book explains complex world of personalized medicine

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

BioView, ScreenCell enter collaboration agreement for imaging of CTC

Study shows cells from different Parkinson’s patients have unique drug responses

Researchers discover new gene mutations associated with megalencephaly

Millennium introduces novel pharmacogenetic testing

New paper discusses potential of tumor-derived microvesicles

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Shanghai Institutes of Preventative Medicine, Gentris sign MOU to advance personalized medicine

Variations in microRNA expression within breast tumors can lead to sampling bias

Enzo Biochem third quarter total revenue increases 4% to $26 million

Sapio announces availability of Exemplar Biomarker Discovery LIMS

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Affymetrix, Leica Microsystems enter worldwide collaboration on RNA ISH analysis

Personalized medicine and the Human Genome Project

Smoker's genetic makeup can help predict response to drug therapy

BHD launches Statin Induced Myopathy Genotype test

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News